PMID- 16902264
OWN - NLM
STAT- MEDLINE
DCOM- 20070402
LR  - 20221207
IS  - 0918-8959 (Print)
IS  - 0918-8959 (Linking)
VI  - 53
IP  - 5
DP  - 2006 Oct
TI  - Long-term effects of recombinant human insulin-like growth factor I treatment on 
      glucose and lipid metabolism and the growth of a patient with congenital 
      generalized lipodystrophy.
PG  - 639-45
AB  - Congenital generalized lipodystrophy (CGL) is a disease characterized by 
      generalized lack of body fat, insulin resistance, hypertriglyceridemia, and fatty 
      liver. We studied the long-term effects of recombinant human insulin-like growth 
      factor I (rhIGF-I) treatment on glucose and lipid metabolism and the growth in a 
      patient with CGL. During rhIGF-I treatment, the serum triglyceride level was 
      maintained almost within the normal range, and the plasma glycosylated hemoglobin 
      A1c (HbA1c) levels were maintained under 8.0% (5.8%-7.9%). Thus, rhIGF-I 
      treatment was effective in lowering glucose and triglyceride levels over the 
      long-term in a CGL patient. However, it was difficult to suppress the patient's 
      voracious appetite. Although serum total IGF-I levels were extremely high 
      (1000-1700 ng/ml), growth was not accelerated after the start of rhIGF-I 
      treatment, likely because of normal IGF binding protein 3 (IGFBP-3) levels. 
      During rhIGF-I treatment, the patient developed a recurrence of mild hypertrophic 
      cardiomyopathy and a mild elevation of intraocular pressure.
FAU - Satoh, Mari
AU  - Satoh M
AD  - First Department of Pediatrics, Toho University School of medicine, Oomorinishi, 
      Tokyo, Japan.
FAU - Yoshizawa, Atsuko
AU  - Yoshizawa A
FAU - Takesue, Masarou
AU  - Takesue M
FAU - Saji, Tsutomu
AU  - Saji T
FAU - Yokoya, Susumu
AU  - Yokoya S
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20060811
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Blood Proteins)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Recombinant Proteins)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adolescent
MH  - Blood Proteins/analysis
MH  - Female
MH  - Glucose/*metabolism
MH  - Glucose Tolerance Test
MH  - Glycated Hemoglobin/analysis
MH  - Growth and Development/*drug effects
MH  - Humans
MH  - Insulin-Like Growth Factor I/adverse effects/analysis/*therapeutic use
MH  - Lipid Metabolism/*drug effects
MH  - Lipodystrophy, Congenital Generalized/*drug therapy
MH  - Recombinant Proteins/therapeutic use
MH  - Time
EDAT- 2006/08/12 09:00
MHDA- 2007/04/03 09:00
CRDT- 2006/08/12 09:00
PHST- 2006/08/12 09:00 [pubmed]
PHST- 2007/04/03 09:00 [medline]
PHST- 2006/08/12 09:00 [entrez]
AID - JST.JSTAGE/endocrj/K06-014 [pii]
AID - 10.1507/endocrj.k06-014 [doi]
PST - ppublish
SO  - Endocr J. 2006 Oct;53(5):639-45. doi: 10.1507/endocrj.k06-014. Epub 2006 Aug 11.